You are here

  • Home
  • Archive
  • Volume 81, Issue 12
  • Response to: ‘Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’’ by Satis et al

Article metrics

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’’ by Satis et al
Free

 

Online download statistics by month:

Online download statistics by month: September 2020 to March 2024

AbstractFullPdf
Sep 202064638
Oct 202022222028
Nov 202011011114
Dec 202014136
Jan 2021363518
Feb 202114149
Mar 2021413911
Apr 202111106
May 202151516
Jun 2021262412
Jul 2021363510
Aug 2021292910
Sep 202122185
Oct 2021403920
Nov 2021383818
Dec 2021757412
Jan 202237368
Feb 202229295
Mar 202234335
Apr 202228278
May 2022312910
Jun 202235333
Jul 2022343310
Aug 202239393
Sep 202232308
Oct 2022353314
Nov 202230530134
Dec 202228128023
Jan 2023474717
Feb 2023575613
Mar 202320208
Apr 2023151519
May 2023373715
Jun 202318182
Jul 2023181517
Aug 202316165
Sep 2023303011
Oct 2023282815
Nov 2023232313
Dec 2023161610
Jan 202425219
Feb 202412129
Mar 20248834
Total21192078521